223 related articles for article (PubMed ID: 34411403)
1. The pathogenesis of melasma and implications for treatment.
Artzi O; Horovitz T; Bar-Ilan E; Shehadeh W; Koren A; Zusmanovitch L; Mehrabi JN; Salameh F; Isman Nelkenbaum G; Zur E; Sprecher E; Mashiah J
J Cosmet Dermatol; 2021 Nov; 20(11):3432-3445. PubMed ID: 34411403
[TBL] [Abstract][Full Text] [Related]
2. Histological changes in facial melasma after treatment with triple combination cream with or without oral tranexamic acid and/or microneedling: A randomised clinical trial.
Cassiano DP; Espósito ACC; Hassun KM; Lima MMDA; Lima EVA; Miot LDB; Miot HA; Bagatin E
Indian J Dermatol Venereol Leprol; 2022; 88(6):761-770. PubMed ID: 35389028
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Pathology of Melasma and Its Clinical Implications.
Kwon SH; Hwang YJ; Lee SK; Park KC
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240341
[TBL] [Abstract][Full Text] [Related]
4. Melasma: histopathological characteristics in 56 Korean patients.
Kang WH; Yoon KH; Lee ES; Kim J; Lee KB; Yim H; Sohn S; Im S
Br J Dermatol; 2002 Feb; 146(2):228-37. PubMed ID: 11903232
[TBL] [Abstract][Full Text] [Related]
5. Melasma: Updates and perspectives.
Kwon SH; Na JI; Choi JY; Park KC
Exp Dermatol; 2019 Jun; 28(6):704-708. PubMed ID: 30422338
[TBL] [Abstract][Full Text] [Related]
6. Histopathological comparison of lesional and perilesional skin in melasma: A cross-sectional analysis.
Gautam M; Patil S; Nadkarni N; Sandhu M; Godse K; Setia M
Indian J Dermatol Venereol Leprol; 2019; 85(4):367-373. PubMed ID: 30516167
[TBL] [Abstract][Full Text] [Related]
7. The Vascular Component of Melasma: A Systematic Review of Laboratory, Diagnostic, and Therapeutic Evidence.
Masub N; Nguyen JK; Austin E; Jagdeo J
Dermatol Surg; 2020 Dec; 46(12):1642-1650. PubMed ID: 33252894
[TBL] [Abstract][Full Text] [Related]
8. Ultrastructural characterization of damage in the basement membrane of facial melasma.
Espósito ACC; Brianezi G; de Souza NP; Santos DC; Miot LDB; Miot HA
Arch Dermatol Res; 2020 Apr; 312(3):223-227. PubMed ID: 31531731
[TBL] [Abstract][Full Text] [Related]
9. Melasma: a review.
Victor FC; Gelber J; Rao B
J Cutan Med Surg; 2004; 8(2):97-102. PubMed ID: 15685388
[TBL] [Abstract][Full Text] [Related]
10. Dermal Pathology in Melasma: An Update Review.
Phansuk K; Vachiramon V; Jurairattanaporn N; Chanprapaph K; Rattananukrom T
Clin Cosmet Investig Dermatol; 2022; 15():11-19. PubMed ID: 35023942
[TBL] [Abstract][Full Text] [Related]
11. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma.
Grimes PE; Yamada N; Bhawan J
Am J Dermatopathol; 2005 Apr; 27(2):96-101. PubMed ID: 15798432
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ex vivo melanogenic response to UVB, UVA, and visible light in facial melasma and unaffected adjacent skin.
Alcantara GP; Esposito ACC; Olivatti TOF; Yoshida MM; Miot HA
An Bras Dermatol; 2020; 95(6):684-690. PubMed ID: 33010989
[TBL] [Abstract][Full Text] [Related]
13. Understanding Melasma-How Can Pharmacology and Cosmetology Procedures and Prevention Help to Achieve Optimal Treatment Results? A Narrative Review.
Piętowska Z; Nowicka D; Szepietowski JC
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231404
[TBL] [Abstract][Full Text] [Related]
14. Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study.
Attwa E; Khater M; Assaf M; Haleem MA
Int J Dermatol; 2015 Feb; 54(2):235-44. PubMed ID: 25266556
[TBL] [Abstract][Full Text] [Related]
15. Exploring pathways for sustained melanogenesis in facial melasma: an immunofluorescence study.
Espósito ACC; Brianezi G; de Souza NP; Miot LDB; Marques MEA; Miot HA
Int J Cosmet Sci; 2018 Aug; 40(4):420-424. PubMed ID: 29846953
[TBL] [Abstract][Full Text] [Related]
16. Exploratory Study of Epidermis, Basement Membrane Zone, Upper Dermis Alterations and Wnt Pathway Activation in Melasma Compared to Adjacent and Retroauricular Skin.
Espósito ACC; Brianezi G; de Souza NP; Miot LDB; Miot HA
Ann Dermatol; 2020 Apr; 32(2):101-108. PubMed ID: 33911720
[TBL] [Abstract][Full Text] [Related]
17. The evolution of melasma therapy: targeting melanosomes using low-fluence Q-switched neodymium-doped yttrium aluminium garnet lasers.
Kauvar AN
Semin Cutan Med Surg; 2012 Jun; 31(2):126-32. PubMed ID: 22640433
[TBL] [Abstract][Full Text] [Related]
18. Adaptability of melanocytes post ultraviolet stimulation in patients with melasma.
Wang YJ; Chang CC; Wu YH; Huang L; Shen JW; Lu ME; Chiang HM; Lin BS
Lasers Surg Med; 2023 Sep; 55(7):680-689. PubMed ID: 37365922
[TBL] [Abstract][Full Text] [Related]
19. Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology.
Alfredo MG; Maribel PM; Eloy PR; Susana GE; Luis LGS; Carmen GM
Exp Dermatol; 2023 May; 32(5):611-619. PubMed ID: 36682042
[TBL] [Abstract][Full Text] [Related]
20. Treatment of melasma with topical agents, peels and lasers: an evidence-based review.
Rivas S; Pandya AG
Am J Clin Dermatol; 2013 Oct; 14(5):359-76. PubMed ID: 23881551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
